Table 3 Effect of myocardial infarction and cardiac hypertrophy on tumor progression: evidence from in vitro studies
Model | Exposure | Proliferation | Invasion/migration | Interpretation | Refs. |
|---|---|---|---|---|---|
Colon cancer cells (HT-29) | SerpinA3/10 ng/mL | ↑ | – | SerpinA3 and SerpinA1 promoted colon cancer cell proliferation | [16] |
SerpinA1/50 ng/mL | ↑ | – | |||
Fibronectin/20 mcg/mL | ↔ | – | |||
Paraoxonase 1/10 mM | ↔ | – | |||
Ceruloplasmin 0.1 mcM | ↔ | – | |||
Breast cancer cells (PyMT) | Serum of TAC-operated mice with PyMT model/48 h | ↑↑ | – | Periostin was increased in early cardiac remodeling in TAC mice and promoted breast and lung cancer cell proliferation | [23] |
Serum from TAC-operated mice without cancer/48 h | ↑ | – | |||
Periostin 2000–4000 ng/mL/48 h | ↑ | – | |||
Periostin 1000 ng/mL/48 h | ↔ | – | |||
Periostin-depleted serum of TAC-operated mice with PyMT model/48 h | ↔ | – | |||
Lung cancer cells (LLC) | Serum from TAC-operated mice with LLC model/48 h | ↑ | – | ||
Serum from TAC mice-operated mice without cancer/48 h | ↑ | – | |||
Periostin 2000–4000 ng/mL/48 h | ↑ | – | |||
Periostin 1000 ng/mL/48 h | ↔ | – | |||
PyMT cells | Serum from low-dose PE-infused mice/48 h | ↑ | – | Serum derived from PE-induced cardiac remodeling mice enhanced breast cancer cell proliferation | [25] |
PyMT cells | Serum from AFT-3 transgenic mice/48 h | ↑ | – | Cardiac remodeling in AFT-3 transgenic mice without pressure overload increased breast and lung cancer cells growth and invasiveness | [24] |
Serum from AFT-3 transgenic mice + doxycycline/48 h | ↑ | – | |||
LLC cells | Serum from AFT-3 transgenic mice/48 h | ↑ | – | ||
LLC cells | Erastin/20 mcM/24 h | ↓↓ | ↓↓ | MI-derived EXO attenuated lung cancer and osteosarcoma cells | [18] |
Erastin/20 mcM/24 h + Sham-EXO 1 mcg/mL/24 h | ↓↓ | ↓↓ | |||
Erastin/20 mcM/24 h + MI-EXO 1 mcg/mL/24 h | ↓ | ↓ | |||
Osteosarcoma cells (K7M2) | Erastin/5 mcM/24 h | ↓↓ | ↓↓ | ||
Erastin/5 mcM/24 h + Sham-EXO 1 mcg/mL/24 h | ↓↓ | ↓↓ | |||
Erastin/5 mcM/24 h + MI-EXO 1 mcg/mL/24 h | ↓ | ↓ | |||
LLC cells | Erastin/20 mcM/24 h | – | ↓↓↓ | MI-derived EXO further enhanced antiferroptotic activity of Fer-1 in erastin-induced suppression of invasion and migration | |
Erastin/20 mcM/24 h + Fer-1 2 mcM/24 h | – | ↓↓ | |||
Erastin/20 mcM/24 h + Fer-1 2 mcM/24 h + Sham-EXO 1 mcg/mL/24 h | – | ↓↓ | |||
Erastin/20 mcM/24 h + Fer-1 2 mcM/24 h + MI-EXO 1 mcg/mL/24 h | – | ↓ | |||
LLC cells | miR-22-3p mimics | ↔ | – | miR-22-3p attenuated erastin-induced ferroptosis | |
Erastin/20 mcM/24 h | ↓↓ | – | |||
Erastin/20 mcM/24 h + miR-22-3p mimics | ↓ | – | |||
AMO-22-3p | ↔ | – | |||
Erastin/20 mcM/24 h | ↓↓ | – | |||
Erastin/20 mcM/24 h + AMO-22-3p | ↓↓↓ | – |